Ilumetri from Almirall - targeted psoriasis biologic locks in steady European growth

By Julian Reed, ad hoc news New Launch Desk. Reviewed June 30, 2026, 7:11 PM ET. Details in the imprint.

Ilumetri is one of those drugs you only notice when you see the chunky prefilled syringe on a dermatologist’s desk, sitting in a silver tray next to alcohol swabs. The psoriasis biologic from Almirall is dosed just four times a year after the loading phase, aiming to keep plaques and itching under tight control.

What Ilumetri actually is

Ilumetri is the brand Almirall uses in Europe for tildrakizumab, a humanized monoclonal antibody targeting the interleukin-23 p19 subunit to treat moderate-to-severe plaque psoriasis. The same molecule is marketed as Ilumya by Sun Pharma in the US, but Almirall holds European rights and focuses on the EU and UK.

According to Almirall’s own product information, Ilumetri is indicated for adults who are candidates for systemic therapy and is delivered as a 100 mg solution for injection in a prefilled syringe. Patients start with injections at weeks 0 and 4, then move to a maintenance schedule of one injection every 12 weeks, which is a key practical selling point for dermatology clinics.

Dosing, efficacy and patient experience

European summary-of-product-characteristics documents state that the recommended dose of Ilumetri is 100 mg subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. In some patients with higher body weight or insufficient early response, dermatologists can consider a 200 mg dose, although 100 mg remains the standard starting point.

Phase 3 data in the reSURFACE trials, which underpin Ilumetri’s European approval, showed that a high proportion of tildrakizumab-treated patients achieved a 75% reduction in psoriasis area and severity (PASI 75) compared with placebo and etanercept, and that many patients sustained responses over long-term follow-up. In plain terms, for a substantial share of patients, angry red plaques fade, scaling declines, and the daily discomfort of chronic psoriasis becomes more manageable.

European footprint and pricing reality

For US investors, the key point is that Ilumetri is a Europe-centered product: it is approved in major EU markets such as Germany and Spain, the UK, and several other territories, but not sold under the Ilumetri brand in the US. In Germany, for example, Ilumetri 100 mg has been available since 2018 and is typically reimbursed under statutory health insurance when prescribed by dermatologists.

Public list prices vary by country and are often subject to confidential rebates, but European health-technology assessments have flagged tildrakizumab as a mid- to high-cost biologic relative to older systemic therapies. That places Ilumetri squarely in the premium biologics segment, vying with rivals such as ustekinumab, guselkumab and risankizumab for dermatologists’ attention and payer budgets. In practice, clinicians balance the 12-week dosing convenience against the cost and individual patient response.

Almirall’s strategy and competition

Almirall’s management has consistently highlighted dermatology, and psoriasis specifically, as a core strategic pillar in quarterly results. CEO Carlos Gallardo has pointed to biologics like Ilumetri as drivers of mid-term revenue growth in Europe, complementing topical treatments and other systemic drugs in the portfolio. In earnings calls, executives describe psoriasis as an area where high-value patients stick with therapy for years, creating recurring revenue streams rather than one-off sales.

The competitive landscape is intense. Several Big Pharma and specialty players now market IL-17, IL-23 and TNF inhibitors for psoriasis, with newer entrants sometimes targeting complete skin clearance as an endpoint. Yet Ilumetri’s relatively infrequent dosing offers an operational advantage for busy clinics: fewer appointments, simpler scheduling, and potentially higher adherence compared with drugs requiring monthly or even biweekly injections. Those everyday logistics matter for dermatologists running crowded practices.

What dermatologists and patients notice

In a typical European clinic, a nurse draws a line on a laminated calendar, marking the next 12-week injection slot for each Ilumetri patient. The syringe itself is designed for subcutaneous administration, with a clear barrel and color-coded cap that makes it easy to distinguish from other biologics in the fridge. After the alcohol swab’s sharp smell fades, many patients describe the injection as tolerable, more like a firm pinch than a deep jab.

Clinical trial publications note that common adverse reactions include upper respiratory infections and injection-site reactions, but serious side effects are relatively infrequent. Prescribers still screen for infections and monitor patients, particularly those with comorbidities. Over time, for responders, the visible plaques on elbows, knees and scalp often thin out, which can translate into practical benefits: fewer flakes on dark clothing, less burning after hot showers, and a quieter, less demanding skin-care routine.

Relevance for US investors watching Almirall

For US-based investors, Ilumetri matters less as a direct US sales story and more as a window into Almirall’s dermatology franchise in Europe. The product is part of a biologic portfolio that the company has been nurturing as it shifts its center of gravity from primary-care generics to specialty skin treatments. As biosimilar competition grows in other segments, branded biologics such as Ilumetri help stabilize revenue and differentiate Almirall from more diversified drug makers.

Almirall stock is listed in euros on the Spanish exchange (BME/EUR: ALM) and does not have a US-listed ADR. Shares of Almirall trade as a midsize European pharma name, with Ilumetri one of several contributors to dermatology revenue rather than a lone blockbuster.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.